| Title |
SPIRIT 2 – STI571 Prospective International Randomised Trial 2. A phase III prospective randomized comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia |
| Scientific Title |
SPIRIT 2 – STI571 Prospective International Randomised Trial 2 |
| Short Title |
SPIRIT 2 |
| Trialgroup |
Newcastle University |
| Type of Trial |
randomized, open-label, multicentric, prospective |
| Disease |
Chronic myeloic leukemia(CML) Chronic Phase
|
| Age |
>= 18 years |
| Status |
Active |
| Start of Recruitment |
04.02.2010 |
| Leader |
O’Brien,, Dr. med., Stephen |
| Contactperson |
Study Centre
Hedgley, Corinne
|
| Centre of Trial |
Newcastle University Medical School |
| Shortprotocol |
Shortprotocol |
created 